Evaluation of damaged small intestine of mouse following methotrexate administration

Michihiko Nakamaru, Yasuhiro Masubuchi, Shizuo Narimatsu, Shoji Awazu, Toshiharu Horie

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Methotrexate (MTX) treatment causes damage to the small intestine, resulting in malabsorption and diarrhea. The active and passive transport capacities of the small intestine are decreased by the treatment. The purpose of this study was to evaluate the damage to the small intestine of mice caused by MTX administration by examining the permeability of the paracellular pathway of the small intestinal epithelium. Methods: MTX was administered orally to male ddY mice once daily for 1-6 days. The permeability of the small intestine to the nonabsorbable markers phenol red (PR) and fluorescein isothiocyanate (FITC) dextrans was examined using everted segments of the intestine. Results: PR and FITC dextran permeation through the small intestine increased significantly in parallel with changes in body weight of the mice, wet weight of the small intestine and chemical composition of the small intestinal epithelium. Conclusions: In addition to changes in permeation through the transcellular pathway reported previously, this study revealed that MTX treatment disorders the paracellular barrier function of the small intestinal epithelium, resulting in increased permeation of nonabsorbable markers via the paracellular pathway of the small intestinal mucosa. The present approach to the examination of the barrier function of the intestinal epithelium could be of great use in evaluating the damage to the small intestine and malabsorption.

Original languageEnglish
Pages (from-to)98-102
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume41
Issue number2
DOIs
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Methotrexate
Small Intestine
Intestinal Mucosa
Permeation
Phenolsulfonphthalein
Permeability
Transcytosis
Body Weight Changes
Active Biological Transport
Intestines
Chemical analysis
Diarrhea
Weights and Measures
fluorescein isothiocyanate dextran

Keywords

  • Dextran
  • Intestinal damage
  • Malabsorption
  • Methotrexate
  • Small intestine

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Evaluation of damaged small intestine of mouse following methotrexate administration. / Nakamaru, Michihiko; Masubuchi, Yasuhiro; Narimatsu, Shizuo; Awazu, Shoji; Horie, Toshiharu.

In: Cancer Chemotherapy and Pharmacology, Vol. 41, No. 2, 1998, p. 98-102.

Research output: Contribution to journalArticle

Nakamaru, Michihiko ; Masubuchi, Yasuhiro ; Narimatsu, Shizuo ; Awazu, Shoji ; Horie, Toshiharu. / Evaluation of damaged small intestine of mouse following methotrexate administration. In: Cancer Chemotherapy and Pharmacology. 1998 ; Vol. 41, No. 2. pp. 98-102.
@article{fb21a3e10a5046ee9cf9d64283906a83,
title = "Evaluation of damaged small intestine of mouse following methotrexate administration",
abstract = "Purpose: Methotrexate (MTX) treatment causes damage to the small intestine, resulting in malabsorption and diarrhea. The active and passive transport capacities of the small intestine are decreased by the treatment. The purpose of this study was to evaluate the damage to the small intestine of mice caused by MTX administration by examining the permeability of the paracellular pathway of the small intestinal epithelium. Methods: MTX was administered orally to male ddY mice once daily for 1-6 days. The permeability of the small intestine to the nonabsorbable markers phenol red (PR) and fluorescein isothiocyanate (FITC) dextrans was examined using everted segments of the intestine. Results: PR and FITC dextran permeation through the small intestine increased significantly in parallel with changes in body weight of the mice, wet weight of the small intestine and chemical composition of the small intestinal epithelium. Conclusions: In addition to changes in permeation through the transcellular pathway reported previously, this study revealed that MTX treatment disorders the paracellular barrier function of the small intestinal epithelium, resulting in increased permeation of nonabsorbable markers via the paracellular pathway of the small intestinal mucosa. The present approach to the examination of the barrier function of the intestinal epithelium could be of great use in evaluating the damage to the small intestine and malabsorption.",
keywords = "Dextran, Intestinal damage, Malabsorption, Methotrexate, Small intestine",
author = "Michihiko Nakamaru and Yasuhiro Masubuchi and Shizuo Narimatsu and Shoji Awazu and Toshiharu Horie",
year = "1998",
doi = "10.1007/s002800050714",
language = "English",
volume = "41",
pages = "98--102",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Evaluation of damaged small intestine of mouse following methotrexate administration

AU - Nakamaru, Michihiko

AU - Masubuchi, Yasuhiro

AU - Narimatsu, Shizuo

AU - Awazu, Shoji

AU - Horie, Toshiharu

PY - 1998

Y1 - 1998

N2 - Purpose: Methotrexate (MTX) treatment causes damage to the small intestine, resulting in malabsorption and diarrhea. The active and passive transport capacities of the small intestine are decreased by the treatment. The purpose of this study was to evaluate the damage to the small intestine of mice caused by MTX administration by examining the permeability of the paracellular pathway of the small intestinal epithelium. Methods: MTX was administered orally to male ddY mice once daily for 1-6 days. The permeability of the small intestine to the nonabsorbable markers phenol red (PR) and fluorescein isothiocyanate (FITC) dextrans was examined using everted segments of the intestine. Results: PR and FITC dextran permeation through the small intestine increased significantly in parallel with changes in body weight of the mice, wet weight of the small intestine and chemical composition of the small intestinal epithelium. Conclusions: In addition to changes in permeation through the transcellular pathway reported previously, this study revealed that MTX treatment disorders the paracellular barrier function of the small intestinal epithelium, resulting in increased permeation of nonabsorbable markers via the paracellular pathway of the small intestinal mucosa. The present approach to the examination of the barrier function of the intestinal epithelium could be of great use in evaluating the damage to the small intestine and malabsorption.

AB - Purpose: Methotrexate (MTX) treatment causes damage to the small intestine, resulting in malabsorption and diarrhea. The active and passive transport capacities of the small intestine are decreased by the treatment. The purpose of this study was to evaluate the damage to the small intestine of mice caused by MTX administration by examining the permeability of the paracellular pathway of the small intestinal epithelium. Methods: MTX was administered orally to male ddY mice once daily for 1-6 days. The permeability of the small intestine to the nonabsorbable markers phenol red (PR) and fluorescein isothiocyanate (FITC) dextrans was examined using everted segments of the intestine. Results: PR and FITC dextran permeation through the small intestine increased significantly in parallel with changes in body weight of the mice, wet weight of the small intestine and chemical composition of the small intestinal epithelium. Conclusions: In addition to changes in permeation through the transcellular pathway reported previously, this study revealed that MTX treatment disorders the paracellular barrier function of the small intestinal epithelium, resulting in increased permeation of nonabsorbable markers via the paracellular pathway of the small intestinal mucosa. The present approach to the examination of the barrier function of the intestinal epithelium could be of great use in evaluating the damage to the small intestine and malabsorption.

KW - Dextran

KW - Intestinal damage

KW - Malabsorption

KW - Methotrexate

KW - Small intestine

UR - http://www.scopus.com/inward/record.url?scp=0031882950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031882950&partnerID=8YFLogxK

U2 - 10.1007/s002800050714

DO - 10.1007/s002800050714

M3 - Article

C2 - 9443621

AN - SCOPUS:0031882950

VL - 41

SP - 98

EP - 102

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -